Granules India and Ajinomoto OmniChem create jv in India
Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh
The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.
Construction of the facility will start in November and should be completed towards the end of 2012.
The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.
Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.
‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.
Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.
Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.
You may also like
Trending Articles
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance
GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors
GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer